{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:22Z","timestamp":1793142742981,"version":"4.5.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.<\/jats:p>","DOI":"10.1182\/hematology.2021000232","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:18:26Z","timestamp":1639138706000},"page":"55-58","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Upfront therapy: the case for continuous treatment"],"prefix":"10.1182","volume":"2021","author":[{"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; and The Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"4","key":"2021121012083142100_hem2021000232C1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2021121012083142100_hem2021000232C2","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2021121012083142100_hem2021000232C3","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2021121012083142100_hem2021000232C4","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2021121012083142100_hem2021000232C5","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","article-title":"The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy","volume":"48","author":"Tam","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021121012083142100_hem2021000232C6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121012083142100_hem2021000232C7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"10277","key":"2021121012083142100_hem2021000232C8","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase \u00bd study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"25","key":"2021121012083142100_hem2021000232C9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10232","key":"2021121012083142100_hem2021000232C10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2021121012083142100_hem2021000232C11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2021121012083142100_hem2021000232C12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2021121012083142100_hem2021000232C13","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121012083142100_hem2021000232C14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"2021121012083142100_hem2021000232C15","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021121012083142100_hem2021000232C16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamaoncol.2017.5604","article-title":"Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials","volume":"4","author":"O'Brien","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"2021121012083142100_hem2021000232C17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"2021121012083142100_hem2021000232C18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"15, suppl","key":"2021121012083142100_hem2021000232C19","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2021.39.15_suppl.7509","article-title":"Acalabrutinib\u00b1obinutuzumab versus obinutuzumab\u2009\u2009+\u2009\u2009chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: elevate-TN four-year follow up","volume":"39","author":"Sharman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021121012083142100_hem2021000232C20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121012083142100_hem2021000232C21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"19","key":"2021121012083142100_hem2021000232C22","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021121012083142100_hem2021000232C23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"2021121012083142100_hem2021000232C24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2021121012083142100_hem2021000232C25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"34","key":"2021121012083142100_hem2021000232C26","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"2021121012083142100_hem2021000232C27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"2021121012083142100_hem2021000232C28","article-title":"Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax+rituximab retreatment in relapsed or refractory CLL: phase 3 MURANO substudy","author":"Wu"},{"key":"2021121012083142100_hem2021000232C29","doi-asserted-by":"crossref","article-title":"Genetic markers and outcome with front line obinutuzumab plus either chlorambucil or venetoclax\u2014updated analysis of the CLL14 trial","author":"Tausch","DOI":"10.1002\/hon.30_2879"},{"issue":"suppl 1","key":"2021121012083142100_hem2021000232C30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-136977","article-title":"Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase 3 CLL14 trial","volume":"136","author":"Al-Sawaf","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2021121012083142100_hem2021000232C31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2021121012083142100_hem2021000232C32","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2019-123327","article-title":"Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"134","author":"Barr","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2021121012083142100_hem2021000232C33","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021121012083142100_hem2021000232C34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-134431","article-title":"long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with 4 years of follow-up in patients with TP53 aberrations (del(17p) or TP53 mutation): a pooled analysis from 4 clinical trials","volume":"136","author":"Allan","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2021121012083142100_hem2021000232C35","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"15, suppl","key":"2021121012083142100_hem2021000232C36","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2021.39.15_suppl.7500","article-title":"First results of a head-to-head trial of acalabrutinib vs ibrutinib in previously treated CLL","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"2021121012083142100_hem2021000232C37","article-title":"First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory CLL\/SLL","author":"Hillmen"},{"issue":"9","key":"2021121012083142100_hem2021000232C38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"issue":"7574","key":"2021121012083142100_hem2021000232C39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"2","key":"2021121012083142100_hem2021000232C40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2017.11.010","article-title":"prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization\/cytogenetics: a real-world clinical experience in the connect CLL registry","volume":"18","author":"Mato","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2021121012083142100_hem2021000232C41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134446","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2021121012083142100_hem2021000232C42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","article-title":"Management of ibrutinib toxicities: a practical guide","volume":"15","author":"Lasica","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2021121012083142100_hem2021000232C43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/55\/1851744\/55tam.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/55\/1851744\/55tam.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:18:54Z","timestamp":1639138734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/55\/483007\/Upfront-therapy-the-case-for-continuous-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000232","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}